MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

NCT06086886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-03-24

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986454 in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

DRUG

BMS-986454

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-16
Primary Completion
2024-12-20
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086886 on ClinicalTrials.gov